CNB-001 a novel curcumin derivative, guards dopamine neurons in MPTP model of Parkinson's disease

Biomed Res Int. 2014:2014:236182. doi: 10.1155/2014/236182. Epub 2014 Jun 17.

Abstract

Copious experimental and postmortem studies have shown that oxidative stress mediated degeneration of nigrostriatal dopaminergic neurons underlies Parkinson's disease (PD) pathology. CNB-001, a novel pyrazole derivative of curcumin, has recently been reported to possess various neuroprotective properties. This study was designed to investigate the neuroprotective mechanism of CNB-001 in a subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rodent model of PD. Administration of MPTP (30 mg/kg for four consecutive days) exacerbated oxidative stress and motor impairment and reduced tyrosine hydroxylase (TH), dopamine transporter, and vesicular monoamine transporter 2 (VMAT2) expressions. Moreover, MPTP induced ultrastructural changes such as distorted cristae and mitochondrial enlargement in substantia nigra and striatum region. Pretreatment with CNB-001 (24 mg/kg) not only ameliorated behavioral anomalies but also synergistically enhanced monoamine transporter expressions and cosseted mitochondria by virtue of its antioxidant action. These findings support the neuroprotective property of CNB-001 which may have strong therapeutic potential for treatment of PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / metabolism
  • Brain / pathology
  • Curcumin / administration & dosage*
  • Curcumin / analogs & derivatives*
  • Dopaminergic Neurons / drug effects
  • Glutathione Peroxidase
  • Humans
  • MPTP Poisoning / drug therapy*
  • MPTP Poisoning / pathology
  • Mice
  • Neuroprotective Agents / administration & dosage
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / pathology
  • Pyrazoles / administration & dosage*

Substances

  • CNB 001
  • Neuroprotective Agents
  • Pyrazoles
  • Glutathione Peroxidase
  • Curcumin